Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
$9.60 0.00 (0.00%)
(As of 11/8/2024 ET)

Haleon - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
5

Based on 6 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 1 has given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$10.95
14.06% Upside
According to the 6 analysts' twelve-month price targets for Haleon, the average price target is $10.95. The highest price target for HLN is $10.95, while the lowest price target for HLN is $10.95. The average price target represents a forecasted upside of 14.06% from the current price of $9.60.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up

HLN Analyst Ratings Over Time

TypeCurrent Forecast
11/9/23 to 11/8/24
1 Month Ago
10/10/23 to 10/9/24
3 Months Ago
8/11/23 to 8/10/24
1 Year Ago
11/9/22 to 11/9/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.95$10.95N/AN/A
Forecasted Upside14.06% Upside8.74% UpsideN/AN/A
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside14.42% Upside10,007.57% Upside7.56% Upside
News Sentiment Rating
Positive News

See Recent HLN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/1/2024UBS Group
4 of 5 stars
G. Delmas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/20/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$9.90 ➝ $10.95+4.78%
8/6/2024Berenberg Bank
2 of 5 stars
B. Davies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
8/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Nicolai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/17/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
3/26/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
8/8/2023Investec
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
5/24/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
4/4/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
1/31/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetGBX 360 ➝ GBX 364

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:24 PM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 25, 2024. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • Haleon plc's stock price has been steadily increasing, reaching $10.12 on the latest trading day, indicating positive momentum.
  • Analysts have given Haleon plc favorable ratings, with some even upgrading it to a "strong-buy" and setting a target price of $10.95, suggesting potential for growth.
  • Haleon plc recently announced a semi-annual dividend, providing investors with a 1.6% dividend yield, which can be attractive for income-focused investors.
  • Institutional investors and hedge funds have been increasing their positions in Haleon plc, indicating confidence in the company's future performance.
  • Haleon plc is engaged in the research, development, and sale of consumer healthcare products globally, presenting diversified revenue streams and market exposure.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • Haleon plc's PEG ratio of 3.12 may indicate that the stock is overvalued relative to its earnings growth potential, potentially leading to limited upside for investors.
  • The company's payout ratio of 36.67% suggests that a significant portion of its earnings is being distributed as dividends, which could limit reinvestment for future growth.
  • Haleon plc's beta of 0.26 indicates low volatility compared to the market, which may result in slower price movements and potentially lower returns for investors seeking high-growth opportunities.
  • While the company has shown positive earnings per share in the past, sell-side analysts forecast a lower EPS for the current year, signaling potential challenges or uncertainties in the company's financial performance.
  • Despite analyst ratings, the recent downgrade by The Goldman Sachs Group from "buy" to "neutral" may raise concerns about the company's future prospects and market sentiment.

HLN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $10.95, with a high forecast of $10.95 and a low forecast of $10.95.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last twelve months. There is currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HLN shares.

According to analysts, Haleon's stock has a predicted upside of 14.06% based on their 12-month stock forecasts.

Over the previous 90 days, Haleon's stock had 1 upgrade by analysts.

Haleon has been rated by research analysts at Morgan Stanley, and UBS Group in the past 90 days.

Analysts like Haleon more than other "medical" companies. The consensus rating for Haleon is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.


This page (NYSE:HLN) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners